



03/16/00

UTILITY

PATENT APPLICATION TRANSMITTAL

(Only for new nonprovisional applications under 37 CFR 1.53(b))

Attorney Docket No.

1194-153

Total Pages

First Named Inventor or Application Identifier

Rolf W. PFIRRMANN

Express Mail Label No.

JP542 U.S. PTO

09/527558

03/16/00

APPLICATION ELEMENTS

See MPEP chapter 600 concerning utility patent application contents.

1. ☒ Fee Transmittal Form
(Submit an original, and a duplicate for fee processing)
2. ☒ Specification Total pages [14]
(preferred arrangement set forth below)
 - Descriptive title of the invention
 - Cross references to Related Applications
 - Statement Regarding Fed sponsored R&D
 - Reference to Microfiche Appendix
 - Background of the Invention
 - Brief Summary of the Invention
 - Brief Description of the Drawings
 - Detailed Description
 - Claims
 - Abstract of the Disclosure
3. ☐ Drawing(s) (35 USC 113) (Total Sheets) []
4. ☒ Oath or Declaration (Total Pages) [2]
 - a. ☒ Newly executed (original or copy)
 - b. ☐ Copy from a prior application
(37 CFR 1.63(d)
(for continuation/divisional with Box 17 completed)
[Note Box 5 below]
5. ☒ Incorporation by Reference (useable if Box 4b is checked) The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.

☐ DELETION OF INVENTOR(S)

Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b)

ADDRESS TO: Assistant Commissioner of Patents
Box Patent Application
Washington, D.C. 20231

6. ☐ Microfiche Computer Program (Appendix)
7. Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary)
 - a. ☐ Computer Readable Copy
 - b. ☐ Paper Copy (identical to computer copy)
 - c. ☐ Statement verifying identity of above copies

ACCOMPANYING APPLICATION PARTS

8. ☒ Assignment Papers (cover sheet & document(s))
9. ☐ 37 CFR 3.73(b) Statement
(when there is an assignee)
- ☐ Power of Attorney
10. ☐ English Translation Document (if applicable)
11. ☐ Information Disclosure Statement /PTO 1449
☐ Copies of IDS Citations
12. ☒ Preliminary Amendment
13. ☒ Return Receipt Postcard (MPEP 503)
(Should be specifically itemized)
14. ☐ Small Entity Statement(s)
☐ Statement Filed in prior application, Status still proper and desired
15. ☐ Certified Copy of Priority Document(s).
(if foreign priority is claimed)
16. ☐ Other:

17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:

☐ Continuation ☐ Divisional ☐ Continuation-in-part (CIP) of prior application No.:

18. CORRESPONDENCE ADDRESS

☐ Customer Number or Bar Code Labelor ☒ Correspondence address below

(Insert Customer No. or Attach bar code label here)

| | | | | | |
|---------|---|-----------|--------------|----------|--------------|
| Name | George R. Repper, Reg. No. 31,414 | | | | |
| Address | Rothwell, Figg, Ernst & Kurz Suite 701-East, 555 13th Street, N.W. | | | | |
| City | Washington | State | D.C. | Zip Code | 20004 |
| Country | U.S.A. | Telephone | 202-783-6040 | Fax | 202-783-6031 |

1194-153
GRR:ymp

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of)
)
Rolf W. PFIRRMANN)
)
Serial No. not yet assigned)
)
Filed: even date herewith)
)
For: ANTICOAGULANT/STERILIZING)
COMPOSITIONS AND METHODS)

PRELIMINARY AMENDMENT

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Please amend the above-identified patent application as follows prior to examination on the merits.

IN THE SPECIFICATION:

Page 1, between lines 2 and 3, insert --CROSS-REFERENCE TO

RELATED APPLICATIONS

This application claims priority from U.S. Provisional application serial no. 60/126,940 filed March 29, 1999, and is a continuation-in-part of U.S. patent application serial number 09/493,797, filed January 28, 2000, which is a continuation of PCT/GB98/02311, filed July 31, 1998.--

009460-8592560


In re: Rolf W. PFIRRMANN

REMARKS

The above amendments are being made to cross-reference related applications.

Respectfully submitted,

By



George R. Repper
Attorney for Applicants
Registration No. 31,414
ROTHWELL, FIGG, ERNST & KURZ, p.c.
Suite 701-E, 555 13th Street, N.W.
Washington, D.C. 20004
Telephone: (202) 783-6040

003100-00000000

1194-153

ANTICOAGULANT/STERILIZING COMPOSITIONS AND METHODS**BACKGROUND OF THE INVENTION****FIELD OF THE INVENTION**

The present invention relates to methods and compositions for preventing thrombosis in or caused by the use of liquid delivery systems, e.g., catheter and port systems.

DESCRIPTION OF THE BACKGROUND ART

Delivery systems are widely used in medicine for introducing liquid material which might include medicaments, nutrition, or other active agents to a patient. Such systems frequently involve the use of catheters which, for many applications, are surgically or intravenously located and stitched into place for long-term administration of the desired material. Typical systems include central catheters such as may be used for total parenteral nutrition (TPN), e.g. when treating short bowel syndrome (for the duration of a patient's life), catheters and drains in hemodialysis and peritoneal dialysis for those with terminal kidney failure, and subcutaneously implanted port systems such as may be used in the treatment of malignant conditions.

One problem associated with the use of liquid delivery systems, e.g., port or catheter-based systems, is that these can give rise to infections which in turn may lead to infected intra-atrial thrombus, embolism, phlebitis, sepsis, endocarditis of the mitral valve, ostium infection, septic lung abscesses, and/or purulent septic pulmonary infarction. One solution to this problem is the use of solutions containing the antibacterial agents taurolidine and/or taurultam. For example, long term continuous infusion of taurolin solutions to prevent septic complications in patients receiving parenteral nutrition has been proposed (see Blenkham, Clinical Nutrition 6(1):35-38, 1987 and Johnston et al., Clinical Nutrition 12(6): 365-358, 1993). More recently in WO98/28027, taurolin solutions have been suggested for use as a temporary seal or flush to prevent or reduce sepsis in port systems or catheters.

Taurolidine and/or taurultam are particularly effective in combating not only infecting bacteria but also in preventing the release of bacterial toxins as well as inactivating any that may be present. These compounds are methylol transfer agents and exert their antibacterial activity by reacting with the bacterial cell wall components and forming covalent bonds.

Despite, therefore, the possibility of quite lengthy residence time in the delivery system, they have been found not to cause any build-up of resistance.

Another problem associated with the use of liquid delivery systems is the potential for blockage of the delivery tubes due to the formation of a coating of fibrin sheath deposits, especially during periods of long term use. The coating starts around a catheter with a thrombus containing fibrin, and progresses into vascularized, fibrous connective tissue. This sheath contains fibroblasts and collagen. Fibrinolytic agents cannot dissolve connective tissue.

Fibrin and/or collagen deposits can result in a significant narrowing of the delivery tubes and, in severe cases, total occlusion. The consequences of the formation of fibrin and/or collagen deposits in liquid delivery systems are therefore clearly dangerous. Moreover, removal or replacement of the delivery system may well have to be carried out operatively, necessitating a further stay in hospital for the patient and further expense.

Removal of a thrombus, especially when located at catheter closures, is difficult and cannot be resolved by fibrinolytic agents such as urokinase, streptokinase, etc., and the following complications are likely to occur. In cavacatheters complications may include thrombosis, embolism, phlebitis and sepsis. In femoral catheters complications may include thrombosis, lethal cases of pulmonary embolism and sepsis. In subclavial-catheters complications may include puncture-proof blockage, thrombosis due to false catheter position, septic complications, total blockage of the vena subclava, and thrombotic changes caused by intima-damage (parietal thromboses between catheter- and vascular wall).

There remains a need in the art for methods and compositions for preventing thrombosis in liquid delivery systems.

SUMMARY OF THE INVENTION

In accordance with the present invention, a composition and method is provided for preventing thrombosis formation on a liquid-contacting surface of a liquid delivery system. The liquid delivery system is connected to a patient for delivery of a liquid to the patient. One embodiment involves contacting the surface with a thrombosis-preventing liquid containing taurolidine, taurultam or a mixture thereof, said thrombosis-preventing liquid further containing an anticoagulant agent. In an alternative embodiment, the liquid-contacting surface of the delivery system is contacted with a solution containing an

anticoagulant agent, and thereafter contacted with a solution containing taurolidine, taurultam or a mixture thereof. The compositions of the invention may be utilized to carry out the above method.

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

5 The compositions and methods of the present invention prevent thrombosis formation in liquid delivery systems such as catheter and port systems, including subcutaneous port systems for use in hemodialysis. Compositions in accordance with the present invention may include an anti-bactericidal-effective amount of a methylol transfer agent such as taurolidine and/or taurultam. The terms taurolidine and/or taurultam as used herein are intended to refer
10 to the compounds taurolidine, taurultam, and there substantial bioequivalents. The taurolidine and/or taurultam preferably is present in a pharmaceutically-acceptable liquid, which in particularly preferred embodiments is an isotonic saline solution.

 Compositions in accordance with the present invention may comprise a liquid containing a thrombosis-preventing amount of an anticoagulant agent. The anticoagulant
15 may be, for example, sodium citrate or heparin. Other anticoagulants which may be included in compositions in accordance with the present invention and utilized with the inventive method include aprotinin, hirudin, desirudin, danaparoid, danaparoid-sodium, pentosan, pentosanpolysulfate-sodium, as well as thienopyridine derivatives such as ticlopidine, clopidogrel or the like, and mixtures thereof.

20 According to one embodiment, the inventive method provides a procedure to prevent deposits of thrombosis of fibrin and/or fibrin/collagen nets by combined application of taurolidine and/or taurultam in suitable isotonic or hypertonic solutions with added anticoagulant. This procedure serves to prevent catheter-sepsis and serious consequences for the patient. Also this combination serves to prevent catheter-blockage, thus avoiding risky
25 surgical interventions for removal of thrombotic plugs (withdrawal of occlusions) or a change of catheters.

 Desirudin, a recombinant hirudin, is an effective anticoagulant according to one embodiment, which in comparison to heparin works as a direct and selective inhibitor of free and fibrin-linked thrombin. The coagulation time of human plasma is prolonged by this
30 agent. A dosage of a few mg added to a taurolidine solution, or a taurolidine/sodium-citrate solution is sufficient, e.g., about 0.1-10mg, preferably about 1-2mg.

00527558-031600

Another coagulation inhibitor apart from heparin-sodium is danaparoid-sodium, an efficient antithrombotic agent including 84% of heparansulphate. This product is derived from porcine mucosa and due to purification steps is free from heparin and/or heparin fragments. This makes it very well tolerated and useful as an alternative to heparin-sodium in cases of heparin-induced thrombocytopenia. As a dosage, between about 7.5-15 anti-factor Xa units may be added to a 100 ml taurolidine solution.

Solutions with thrombocyte aggregation inhibitors or solutions which additionally contain anticoagulants such as citrate-dextrine solutions, citrate-phosphate-dextrose-adenin solutions, sodium citrate-citric acid solutions or heparin, etc., preferably should be filtered sterile after production and filled aseptically into vials of 10 to 100ml. To avoid possible interactions between the added anticoagulants and taurolidine/taurultam, the inventive solutions can also be administered intermittently in two steps to avoid coagulation and formation of plaque in the catheter:

- 1) Instillation of sterile isotonic sodium chloride solution with anticoagulants. If desired, this solution can be aspirated again.
- 2) Thereafter flushing of the catheter with sterile isotonic sodium chloride solution followed by instillation of the taurolidine 2% solution (lock-technique). If desired, the taurolidine solution can be aspirated again after about one hour.

Viewed from one aspect, the invention thus provides a solution suitable for use in a liquid delivery system, e.g., port or catheter-based systems, including hemodialysis systems, comprising taurolidine and/or taurultam in combination with an anticoagulant.

Preferred solutions will contain from 0.5 to 3% by weight of taurolidine, or from 1 to 7.5% by weight taurultam, advantageously 3 to 5%, depending on the solubility of the compound. Solutions containing from 1.0 to 2.0%, preferably about 1.0 % by weight, taurolidine are preferred.

Sodium citrate may be used in the form of anhydrous sodium citrate, but preferably will be used in the form of the dihydrate. Preferred solutions are those containing 0.5 to 3.0% by weight, preferably 1.0 to 2.0%, sodium citrate. Solutions containing about 1.5% by weight, e.g., 1.45% sodium citrate have been found to be isotonic without the need for additional electrolytes and are particularly preferred for use in the invention.

In one embodiment of the invention, the solutions may contain heparin, a heparin derivative or an analog, e.g., pentosan-sodium, in particular heparin-Na or heparin-Ca. The desired amount of heparin will vary from patient to patient but can nevertheless be readily determined by those skilled in the art. An average concentration of heparin can be expected to be in the range of from 1 to 15 U/ml heparin-Na, preferably 1 to 2 U/ml.

The solutions in accordance with the invention will generally be made up in sterile pyrogen-free water and may also contain, for example, inorganic or other salts or other components to render them isotonic. Cations and anions such as sodium, potassium, calcium, chloride, lactate, maleate and bicarbonate are suitable for use as electrolytes. Sodium chloride is particularly suitable, e.g., in an amount of about 0.45% by weight.

Parenterally acceptable polyols may, for example, also be present since these have been observed to increase the overall intravenous tolerance of tauridins. Suitable polyols include carbohydrates, e.g., hexoses such as glucose and fructose (or mixtures of these such as invert sugar), pentoses such as xylose or polysaccharides such as dextran or hydrolyzed starch; glycerol and sugar alcohols such as sorbitol, mannitol or xylitol.

The concentration of the polyol can usefully be in the range 3 to 40% by weight. In the case of glucose, the concentration may be in the range 10 to 30% by weight, preferably 20%.

The solutions may also contain polyvinylpyrrolidone (PVP). This may be incorporated into the solutions at a concentration of, e.g. from 4 to 7% by weight. A solution containing 5% PVP is preferred. This assists in solubilizing the active substance and contributes also to the oncotic pressure of the solution. The molecular weight of the PVP should not be greater than 50,000 and is preferably less than 10,000, for example between 7,000 and 9,000. Kollidone 17 as sold by BASF, specially purified (substantially free of peroxide as taught in PCT/GB97/00069) is relatively quickly resorbed and excreted renally.

The pH of the solution will preferably be in the range 7 to 8, e.g. about 7.3-7.4. While any component present in the solution may itself serve to yield a solution with the desired pH, conventional buffers or pH adjusting agents may be used.

Such solutions are used in accordance with the present invention in conjunction with liquid delivery systems, e.g., catheters and port systems. Such solutions may conveniently be used to fill, flush out or seal the delivery system when not in use. Preferably, these may be

used to effectively seal the delivery system between each administration of desired liquid material, such as chemotherapeutic agent or nutrient, or after withdrawal of any blood sample from the reservoir. Should there be any period of time when it is desired not to use the delivery system for administration of chemotherapeutic or other active or nutritional agent, such as is often the case during the cyclical delivery of chemotherapeutic agents or during total parenteral nutrition, the delivery system can be filled with a solution in accordance with the invention to act as an antimicrobial seal. Relatively small volumes (of the order of a few milliliters, e.g. approximately 3 ml) of the solution are required for this. A contact time of about one hour is desirably a minimum, though the seal can be retained for up to twelve hours or more. According to one embodiment, a solution in accordance with the present invention is sealed within the liquid delivery system for at least about 12 hours. A solution in accordance with the present invention which is sealed in the liquid delivery system can be replaced daily. All of these activities can be carried out without any development of resistance or build-up of bacterial toxins such as LPS and exotoxins by resident bacteria. Solutions in accordance with the invention are well tolerated in vivo; there is no toxicity and no side effects have been observed.

Accordingly, viewed from a further aspect the invention provides the use of a solution as herein described as a temporary seal to prevent or reduce blood coagulation in a liquid delivery system. This is of particular application to the use of catheters.

Viewed from another aspect the invention provides the use of a solution as herein described to reduce or prevent blood coagulation associated with the use of subcutaneously-implanted delivery systems.

The solutions of the invention are of particular application to systems which deliver medication from a reservoir via a catheter into the cardiovascular system, such as might be used during chemotherapy. Prior to introducing a cancer chemotherapeutic agent, for example, the taurolidine solution in accordance with the invention (present as a temporary seal) is removed from the catheter or rinsed into the bloodstream using saline. Cancer chemotherapeutic agent as desired is then injected into the chamber and enters into the body over a period of time. Examples of possible such agents include the alkylating agents, such as mitomycin hydrochloride and cyclophosphamide; antimetabolites such as fluorouracil, cytarabine and methotrexate; anti-tumor antibiotics such as bleomycin sulphate, daunorubicin

hydrochloride and idarubicin hydrochloride; alkaloids such as lincristine sulphate and cisplatin such as carboplatin. These agents are administered via the port system in different formulations for several short-term and long-term infusions or for bolus injections.

5 Viewed from a yet further aspect, the invention provides a method of inhibiting blood coagulation in or associated with the use of a liquid delivery system, e.g., a port or catheter-based system including a hemodialysis system in which the system is flushed and/or sealed with a solution according to the invention in an amount effective to inhibit blood coagulation.

10 As indicated above, according to one embodiment, the anticoagulant for use in the present invention is administered as a combined preparation with the taurolidine and/or taurultam solution. However, depending on the nature of the treatment, in other embodiments the anticoagulant solution is administered separately, prior to, during or subsequent to administration of taurolidine and/or taurultam solution.

15 For example, in one embodiment the liquid delivery system is first contacted with a solution containing a thrombosis-preventing amount of an anticoagulant as indicated above, for example, by flushing the device with the anticoagulant solution or injecting the anticoagulant solution into the device and then removing the anticoagulant solution, e.g., by aspiration or flushing. Thereafter, a solution containing taurolidine is instilled into the liquid delivery system and preferably held in contact with the internal surfaces thereof for at least
20 about 1 hour.

A particular advantage of the combination of taurolidine, taurultam, sodium citrate and/or organic anticoagulant for thrombus prevention in a catheter system, and also for infection prevention, lies in the unexpectedly small quantities of anticoagulant required, i.e., respectively few milligrams per hundred milliliters are required to prevent fibrin/collagen
25 deposits within the catheter system.

The combination solution has proven to be unexpectedly advantageous for stability of the product, with the combination solution being sterile-filtered with 0.1-0.2 μm filters and thereafter aseptically filled into 10-100 ml serum bottles.

30 It is also possible to sterilize bottles filled with combination solution over a short term with steam, sufficient to inactivate any microorganisms (bioburden) present, without inactivating or substantially reducing the anticoagulation properties of the product.

00527558-031600

When anticoagulants are utilized which do not tolerate heat sterilization, the solution in accordance with the invention may be filtered under aseptic conditions through a filter having sufficiently small pores so as to sterilize the solution, e.g., a 0.1-0.2 micron sterile filter. The thus-filtered solutions then may be filled into 10-100ml vials or bottles and sealed with a rubber stopper and aluminum cap.

Viewed from another aspect the invention thus provides products containing a solution of taurolidine and/or taurultam and a solution containing an anticoagulant selected from sodium citrate, aprotinin, hirudin, desirudin, danaparoid, danaparoid-sodium, heparin, pentosan, pentosanpolysulfate-sodium, as well as thienopyridine derivatives such as ticlopidine, clopidogrel and the like, and mixtures thereof. Low dosages of anticoagulant can be utilized, e.g., about 0.1-10mg, preferably about 1-2mg.

A thrombosis-preventing liquid in accordance with the present invention may contain an anticoagulant material as described above present in the solution in an amount within a range of from about 0.01 to about 5% by weight.

Although the invention has been described with particular reference to the use of taurolidine and/or taurultam in liquid delivery systems, the specific anticoagulants herein described may be utilized in preventing the formation of fibrin collagen deposits in liquid delivery systems, especially within the delivery tubes.

Thus, the invention provides the use of an anticoagulant as herein described to prevent blood coagulation in a liquid delivery system, e.g., a port or catheter-based system.

The invention will be further illustrated by way of the following non-limiting examples.

EXAMPLE 1

2% taurolidine solution and 3% taurolidine solution is prepared in accordance with the present invention as follows.

2% Taurolidine Solution

| <u>Substance</u> | <u>Percent by weight</u> | <u>Amount per liter</u> |
|-----------------------------|--------------------------|-------------------------|
| Taurolidine | 2.0 | 20g |
| Trisodium citrate dihydrate | 3.0 | 30g |
| Water | 95.0 | Adjust to 1L |
| Citric acid monohydrate | 0.024 | 240 mg |
| Total | 100.0 | 1 liter |

pH 7.0 - 7.2 after sterilization

The taurolidine and trisodium citrate dihydrate are dissolved in the water at up to 60°C, cooled down, and the pH adjusted to 7.4 with the citric acid monohydrate and sodium hydroxide. The solution is sterile filtered, filled into 10 - 100 ml serum bottles. To avoid undesirable interactions, sterilization should preferably be done quickly and below 121°C, in relation to the bioburden and the F₀ concept as described, for example, in the British Pharmacopoeia 1998, Appendix XVIII.

3% Taurolidine Solution

| | | | |
|----|-----------------------------|--------------------------|-------------------------|
| 10 | Substance | Percent by weight | Amount per liter |
| | Taurolidine | 3.0 | 30g |
| | Trisodium citrate dihydrate | 3.0 | 30g |
| | Water | 94.0 | Adjust to 1l |
| | Citric acid monohydrate | 0.024 | 245 mg |
| 15 | Total | 100.0 | 1 liter |

pH 7.0 - 7.2 after sterilization

The taurolidine and trisodium citrate dihydrate are dissolved in the water at up to 60°C, cooled down, and the pH adjusted to 7.0-7.2 with the citric acid monohydrate. The solution is sterile filtered, aseptically filled into 10 - 100 ml serum bottles.

To each of the above formulations may be added one or more of the following anticoagulants:

- Heparin-sodium
- Aprotinin
- 25 • Hirudin
- Heparin
- Pentosan-sodium
- Desirudin
- Danaparoid-sodium

30

If separately prepared, the above components are dissolved in the distilled water, sterile filtered, filled into bottles and autoclaved in accordance with bioburden for 15 mins at 100 - 121°C.

00970-85572550

EXAMPLE 2 - PORT DELIVERY SYSTEM

A patient has a port delivery system comprising a polyurethane chamber of approx. 0.5 cm³ volume mounted on a small titanium plate implanted in a small pocket in the pectoral muscle. The tip of a catheter of approx. 0.3mm diameter leading from it has been intubated into one of the major veins and lies close to the point of entry of the vena cava into the right atrium of the heart. After implantation the chamber was flushed through with 2 ml of a sterile 0.9% by weight sodium chloride solution containing 800 I.U. heparin.

The chamber is then filled with approximately 3 ml of a solution according to Example 1 (injected into the chamber by special syringe). The device is then sealed for up to 12 hours or until whenever chemotherapeutic administration is due.

After each treatment with medication, or after use of the chamber to withdraw a sample of venous blood, the delivery system is rinsed meticulously with 10 ml of a sterile 0.9% sodium chloride solution. 2 ml of a solution according to Example 1 are then introduced into the chamber and the needle removed. The port system is then effectively sealed against microbial infection. After being rinsed with saline, further medication may then be introduced when desired and the cycle repeated. Alternatively, the instilled solution can be aspirated before further medication is introduced.

EXAMPLE 3 - CATHETER DELIVERY SYSTEM

A patient undergoing total parenteral nutrition is fitted with a central catheter by known techniques. Nutrition is delivered overnight while the patient is asleep but during the day the catheter is sealed with approximately 3 ml of a solution according to Example 1. This is effective to prevent catheter sepsis and to prevent fibrin and/or collagen deposits within the delivery tubes. Moreover, this has no side effects when it passes into the body when nutrition recommences possibly several hours later overnight.

009271510-031600

CLAIMS

1. A method of preventing thrombosis formation on a liquid-containing surface of a liquid delivery system, the liquid delivery system being connected to a patient for delivery of a liquid to said patient, the method comprising a regimen selected from the group consisting of:
- A) contacting said surface with a thrombosis-preventing liquid containing taurolidine, taurultam or a mixture thereof, said thrombosis-preventing liquid further containing an anticoagulant agent; and
 - B) first contacting said surface with a solution containing a thrombosis-preventing amount of an anticoagulant agent, and thereafter contacting said surface with a solution containing taurolidine, taurultam or a mixture thereof.
2. The method of claim 1 wherein the solution or liquid containing taurolidine, taurultam or mixture thereof is contacted with said surface for at least about 1 hour.
3. The method of claim 2 wherein said solution or liquid containing taurolidine, taurultam or mixture thereof is sealed in said delivery system for a period of at least 12 hours.
4. The method of claim 3 wherein said solution or liquid containing taurolidine, taurultam or mixture thereof which is sealed in said delivery system, is replaced at least about daily.
5. The method of claim 1 wherein, when first contacting said surface with the anticoagulant solution, said surface is flushed with said anticoagulant-containing solution.
6. The method of claim 5 wherein the solution containing taurolidine, taurultam or a mixture thereof is contacted with said surface for at least about 1 hour.
7. The method of claim 6 wherein said solution containing taurolidine, taurultam or a mixture thereof is sealed in said delivery system for a period of at least about 12 hours.
8. The method of claim 7 wherein the solution containing taurolidine, taurultam or a mixture thereof which is sealed in said delivery system is replaced at least about daily.

1 9. The method of claim 1 wherein the anticoagulant-containing solution is contacted with
2 said surface by injecting the anticoagulant-containing solution into said liquid delivery
3 system and then removing said anticoagulant-containing solution from said liquid delivery
4 system.

1 10. The method of claim 9 wherein the solution containing taurolidine, taurultam or a
2 mixture thereof is contacted with said surface for at least about 1 hour.

1 11. The method of claim 10 wherein the solution containing taurolidine, taurultam or a
2 mixture thereof is sealed in said delivery system for a period of at least about 12 hours.

1 12. The method of claim 11 wherein the solution containing taurolidine, taurultam or a
2 mixture thereof which is sealed in said delivery system, is replaced at least about daily.

1 13. The method of claim 1 wherein said solution or liquid containing taurolidine, taurultam
2 or a mixture thereof contains from about 0.5 to about 3% by weight of taurolidine, or from
3 about 1 to about 7.5% by weight of taurultam.

1 14. The method of claim 1 wherein said anticoagulant agent is selected from the group
2 consisting of sodium citrate, aprotinin, hirudin, desirudin, danaparoid, danaparoid-sodium,
3 heparin, pentosan, pentosanpolysulfate-sodium, ticlopidine, clopidogrel, and mixtures
4 thereof.

1 15. The method of claim 14 wherein said anticoagulant is present in an amount within a
2 range of from about 0.1-10mg.

1 16. A composition for use in the method of claim 1, comprising a pharmaceutically-
2 acceptable liquid containing taurolidine, taurultam or a mixture thereof and further including
3 an anticoagulant agent.

00527598-031600
00970-85522560

1 17. The composition of claim 16 wherein said anticoagulant agent is selected from the group
2 consisting of aprotinin, hirudin, desirudin, danaparoid, danaparoid-sodium, pentosan,
3 pentosanpolysulfate-sodium, ticlopidine, clopidogrel, and mixtures thereof.

1 18. The composition of claim 16 wherein said anticoagulant agent is heparin.

1 19. The composition of claim 16 wherein said anticoagulant is sodium citrate.

1 20. The composition of claim 16 wherein said taurolidine is present in an amount of from
2 about 0.5 to about 3% by weight or said taurultam is present in an amount of from about 1 to
3 about 7.5% by weight, and said anticoagulant agent is present in an amount within a range of
4 from about 0.01 to about 5% by weight.

009100-85420000

ABSTRACT OF THE DISCLOSURE

Compositions and methods are provided for preventing formation of thrombosis on a liquid-contacting surface of a liquid delivery system, such as a port, catheter or port-catheter system. The liquid delivery system is connected to a patient for delivery of a liquid to the patient. The method involves contacting the surface with a thrombosis-preventing liquid containing taurolidine, taurultam or a mixture thereof, the thrombosis-preventing liquid further containing an anticoagulant agent. In an alternative embodiment, the liquid-contacting surface of the delivery system is contacted with a solution containing an anticoagulant agent, and thereafter contacted with a solution containing taurolidine, taurultam or a mixture thereof.

0057E0 06542500

Attorney Docket No. 1194-153

DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor of the subject matter which is claimed and for which a patent is sought, on the invention entitled **ANTICOAGULANT/STERILIZING COMPOSITIONS AND METHODS**, the specification of which is attached hereto as Attorney Docket No. 1194-153

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims.

I acknowledge the duty to disclose information which is material to patentability in accordance with Title 37, Code of Federal Regulations, § 1.56(a).

No claim for foreign priority benefits under Title 35, United States Code, § 119 is made and no corresponding foreign applications for patent or inventor's certificate having a filing date before that of the present application have been filed.

I hereby claim the benefit under Title 35, United States Code § 119(e) of any United States provisional application(s) listed below.

60/126,940

March 29, 1999

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, 1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

09/493,797
(Application Serial No.)

January 28, 2000
(Filing Date)

pending
(Status)

PCT/GB98/02311
(Application Serial No.)

July 31, 1998
(Filing Date)

(Status)

I or we hereby appoint the following attorneys to prosecute this application and to transact all business in the Patent and Trademark Office connected therewith, and request that all correspondence about the application be addressed to ROTHWELL, FIGG, ERNST & KURZ, p.c., Suite 701-E, 555 13th Street, N.W., Washington, D.C. 20004

09527558-031600

1194-153

Page 2

G. Franklin Rodwell, Reg. No. 18,125
E. Anthony Figg, Reg. No. 27,195
Barbara G. Ernst, Reg. No. 30,377
George R. Repper, Reg. No. 31,414
Bart G. Newland, Reg. No. 31,282
Vincent M. DeLuca, Reg. No. 32,408
Celine Jimenez Crowson, Reg. No. 40,357
Joseph A. Hynds, Reg. No. 34,627
Mark I. Bowditch, Reg. No. 40,315
Robert J. Jondle, Reg. No. 33,915
Kenneth M. Fagin, Reg. No. 37,615
Stephen B. Parker, Reg. No. 36,631
Don M. Kerr, Reg. No. 22,720
Jeffrey L. Ihnen, Reg. No. 28,957
Stephen A. Saxe, Reg. No. 38,609
Glenn E. Karla, Reg. No. 30,649
Martha Cassidy, Reg. No. 44,066

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application or any patent issuing thereon.

Inventor's Signature Rolf W. Pfirrmann Date March 16, 2000

Inventor's Name: Rolf W. Pfirrmann

Citizenship: Swiss

Residence (City): CH-6006 Lucerne

(State/Foreign Country): Switzerland

Mailing Address: Schädtrütistrasse 27, CH-6006 Lucerne, Switzerland

00527538-031600